Key result
High-dose Sulodexide significantly improved lipid profiles, fibrinogen levels, and plethysmography flow values compared to placebo in patients with stage-II peripheral vascular disease.
Why the study?
Does high-dose glycosaminoglycan (Sulodexide) improve laboratory parameters and instrumental procedures in patients with stage-II peripheral vascular disease?
RCT (n=30)
Double-blind
Does high-dose glycosaminoglycan (Sulodexide) improve laboratory parameters and instrumental procedures in patients with stage-II peripheral vascular disease?
High-dose Sulodexide significantly improves lipid profiles, fibrinogen levels, and plethysmographic flow parameters in patients with stage-II peripheral vascular disease.
Sulodexide improves parameters in stage-II PVD; extends glycosaminoglycan evidence in this RCT.
Thirty patients suffering from peripheral vascular disease (stage-II according to Fontaine) were included in a double-blind study aimed at assessing the efficacy of a high-dose glycosaminoglycan (GAG) (Sulodexide) both in terms of laboratory parameters, such as lipid metabolism and blood coagulation components, and instrumental procedures (strain-gauge plethysmography). Compared with the fifteen control patients (treated with placebo), the fifteen patients treated with Sulodexide showed a significant decrease in blood triglycerides and fibrinogen as well as a significantly increased HDL-cholesterol, and positive instrumental changes: at the end of treatment Peak and Rest Flow values--and consequently also Winsor's index--were significantly increased only in patients treated with Sulodexide.
No takes yet. Share an insight, caveat, or question.
Corsi et al. (1985) conducted an RCT in Peripheral vascular disease (n=30). Sulodexide vs. Placebo was evaluated on Laboratory parameters (lipid metabolism and blood coagulation components) and instrumental procedures (strain-gauge plethysmography). High-dose Sulodexide significantly improved lipid profiles, fibrinogen levels, and plethysmography flow values compared to placebo in patients with stage-II peripheral vascular disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: